Answers are grounded in this paper and cite their sources.
This study shows that an early increase in galectin-3 expression identifies failure-prone hypertrophied hearts. Galectin-3, a macrophage-derived mediator, induces cardiac fibroblast proliferation, collagen deposition, and ventricular dysfunction. This implies that HF therapy aimed at inflammatory responses may need to be targeted at the early stages of HF and probably needs to antagonize multiple inflammatory mediators, including galectin-3.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: